Novo Nordisk Invests Over $6 Bln to Boost Production Capacity

Novo Nordisk will invest over 42 billion Danish kroner ($6.01 billion) to boost manufacturing capacity in Kalundborg, Denmark. Most of the new capacity will be dedicated to manufacturing active pharmaceutical ingredients, including for its blockbuster GLP-1 products for treating diabetes and obesity, which will increase the company’s ability to meet future market demands. Novo Nordisk has been struggling to meet surging demand for its GLP-1 drugs and has been forced to limit supply of lower-strength doses of its Wegovy weight-loss medicine in the U.S. as it seeks to safeguard supplies for current patients.